This inventor holds 8 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent. Top assignees: Billings Pharmaceuticals, Inc., Other. Active years: 1999-2008.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1999-2008
Title: The Innovative Contributions of Ali S Turgiev
Introduction
Ali S Turgiev is a prominent inventor based in Moscow, Russia. He has made significant contributions to the field of pharmaceuticals, particularly in the development of chiral integrin modulators. With a total of eight patents to his name, Turgiev's work has the potential to impact various medical treatments and improve patient outcomes.
Latest Patents
Among his latest patents is the invention titled "Chiral integrin modulators and methods of use thereof." This invention provides enantiomers of ajoene and derivatives of Z(−)-ajoene. The derivatives of Z(−)-ajoene are particularly useful for modulating integrin-mediated functions. They can be applied in treating disorders, diseases, or conditions where integrins play a crucial role. Additionally, these compounds can enhance the condition of tissues for subsequent uses, such as transplantation.
Career Highlights
Throughout his career, Turgiev has worked with notable companies, including Billings Pharmaceuticals, Inc. His innovative approach and dedication to research have led to advancements in the pharmaceutical industry. His work continues to inspire future developments in medical treatments.
Collaborations
Turgiev has collaborated with esteemed colleagues, including Alexander V Tatarintsev and John B Davidson. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Ali S Turgiev's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a significant inventor. His work in developing chiral integrin modulators showcases the potential for advancements in medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile